吉西他滨联合卡培他滨治疗晚期乳腺癌疗效观察.doc

吉西他滨联合卡培他滨治疗晚期乳腺癌疗效观察.doc

  1. 1、本文档共11页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
吉西他滨联合卡培他滨治疗晚期乳腺癌疗效观察

吉西他滨联合卡培他滨治疗晚期乳腺癌疗效观察[摘要] 目的:观察吉西他滨联合卡培他滨治疗晚期乳腺癌的临床疗效和不良反应。方法:吉西他滨1 000 mg/m2,1、8 d;卡培他滨2 500 mg/(m2d),分2次口服,第1~14天,21 d为1个周期。所有患者均接受至少2个周期的化疗。结果:48例患者入组均可评价疗效,CR率为12.5%(6/48),PR率为29.2%(14/48),SD率为20.8%(10/48),PD率为37.5%(18/48)。有效率为41.7%(20/48),临床获益率为62.5%(30/48)。中位随访期10个月,中位TTP 7个月,中位OS 9.5个月,1年生存率为66.7%。主要不良反应为骨髓毒性及手足综合征,Ⅲ度及Ⅳ度白细胞减少为22.9%(11/48),Ⅲ度及Ⅳ度血小板减少为18.8%(9/48)。手足综合征发生率为70.8%,其中,Ⅲ度及Ⅳ度手足综合征发生率为16.7%(8/48)。结论:吉西他滨联合卡培他滨方案治疗蒽环类和紫杉类化疗失败的转移性乳腺癌有较好的疗效,患者耐受性好,值得临床进一步研究。 [关键词] 转移性乳腺癌;化疗;吉西他滨;卡培他滨 [中图分类号] R737.9 [文献标识码]A[文章编号]1674-4721(2011)02(b)-026-03 Clinical experience of gemcitabine combined with capecitabine in treating patients with advanced metastatic breast cancer FU Jing, SHI Shuzhen (Dalian Tumor Hospital, Liaoning Province, Dalian116031,China) [Abstract] Objective: To observe the efficacy and toxicity of the combination of gemcitabine and capecitabine in the treatment of anthracycline and taxane-resistant advanced metastatic breast cancer (MBC) patients. Methods: 48 patients with advanced MBC failed to previous chemotherapy with anthracycline and taxane were enrolled into the study. The patients received gemcitabine 1 000 mg/m2 on days 1, 8, and capecitabine 2 500 mg/(m2?d), bid, on day 1-14, with 21 days as a cycle. Each patient received at least two cycles. Results: Of the 48 patients, 6 cases got complete response, 14 cases got partial response, 10 cases had stable disease,and 18 cases had progressive disease,with the overall response rate was 41.7%(20/48), the clinical benefit rate was 62.5%(30/48). With a median follow-up of 10 months. The median TTP was 7 months. The median OS was 9.5 months. The 1 year survival rate was 66.7%. The main toxic reactions were myelosuppression and hand-foot syndrome, leukopenia (incidence of 22.9% for gradeⅢ+Ⅳ) and hand-foot syndrome (incidence of 70.8%, incidence of 16.7% for gradeⅢ+Ⅳ). Conclusion: The combination of gemcitabine and capecitabine is active in the treatment of anthracycline and taxane-

文档评论(0)

docman126 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

版权声明书
用户编号:7042123103000003

1亿VIP精品文档

相关文档